The U.S. government sued Teva Pharmaceutical Industries Ltd., accusing the drugmaker of causing the submission of false claims to Medicare as a result of kickbacks the company paid for the multiple sclerosis drug Copaxone.
Novavax entered into an agreement to provide the United Kingdom with 60 million doses of the company’s Covid-19 vaccine candidate should NVX-CoV2373 be approved, as well as a late-stage efficacy study in the U.K.
The United States is tying payments for Covid-19 vaccines to timing milestones for production and approval, according to public documents and a Trump administration official, putting pressure on drugmakers including Moderna Inc. to meet ambitious targets.
(Reuters) – Any potential COVID-19 vaccine backed by the Trump administration’s “Operation Warp Speed” program is unlikely to receive a green light from regulators any earlier than November or December, […]
Advanced Care Scripts Inc. will pay $3.5 million to resolve allegations that the Florida-based specialty pharmacy served as a conduit for a Teva Pharmaceutical Industries Ltd. subsidiary to pay kickbacks to Medicare patients, the U.S. Justice Department said.
The United States entered an agreement with drugmaker Moderna Inc. to acquire 100 million doses of the company’s potential COVID-19 vaccine for around $1.5 billion, the company and White House said.
Omeros Corp.’s experimental treatment helped six patients with acute respiratory distress syndrome caused by Covid-19 recover and get discharged from the hospital, sending the drug developer’s shares up 60%.
Nearly 300,000 Americans could be dead from Covid-19 by Dec. 1, University of Washington health experts forecast, although they said 70,000 lives could be saved if people were scrupulous about wearing masks.
Virginia launched the first contact tracing app for the novel coronavirus in the United States that uses new technology from Apple Inc. and Alphabet Inc.’s Google.
Moderna Inc. said smaller volume agreements for the company’s experimental coronavirus vaccine have been priced in the range of $32 to $37 per dose, higher than the price set by the U.S. deal for Pfizer Inc.’s vaccine candidate.
